M
Mark A. Feitelson
Researcher at Temple University
Publications - 102
Citations - 5678
Mark A. Feitelson is an academic researcher from Temple University. The author has contributed to research in topics: Hepatitis B virus & Virus. The author has an hindex of 38, co-authored 100 publications receiving 5146 citations. Previous affiliations of Mark A. Feitelson include Second Military Medical University & Thomas Jefferson University.
Papers
More filters
Journal ArticleDOI
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma
TL;DR: In this paper, a review outlines pathogenic mechanisms that seem to be common to both hepatitis B virus and hepatitis C virus and suggest innovative approaches to the prevention and treatment of HCC.
Journal ArticleDOI
Human viral oncogenesis: a cancer hallmarks analysis.
TL;DR: The Hallmarks of Cancer framework of Hanahan and Weinberg (2000 and 2011) is used to dissect the viral, host, and environmental cofactors that contribute to the biology of multistep oncogenesis mediated by established human oncoviruses.
Journal ArticleDOI
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
Mark A. Feitelson,Alla Arzumanyan,Rob J. Kulathinal,Stacy W. Blain,Randall F. Holcombe,Jamal Mahajna,Maria Marino,María L. Martínez-Chantar,Roman Nawroth,Isidro Sánchez-García,Dipali Sharma,Neeraj K. Saxena,Neetu Singh,Panagiotis J. Vlachostergios,Shanchun Guo,Kanya Honoki,Hiromasa Fujii,Alexandros G. Georgakilas,Alan Bilsland,Amedeo Amedei,Elena Niccolai,Amr Amin,S. Salman Ashraf,Chandra S. Boosani,Gunjan Guha,Maria Rosa Ciriolo,Katia Aquilano,Sophie Chen,Sulma I. Mohammed,Asfar S. Azmi,Dipita Bhakta,Dorota Halicka,W. Nicol Keith,Somaira Nowsheen +33 more
TL;DR: Natural compounds found to inhibit one or more pathways that contribute to proliferation have been found and will be very important for identifying signaling pathways and molecular targets that may provide early diagnostic markers and/or critical targets for the development of new drugs or drug combinations that block tumor formation and progression.
Journal ArticleDOI
Genetic mechanisms of hepatocarcinogenesis.
TL;DR: The observations suggest that there are multiple, perhaps redundant negative growth regulatory pathways that protect cells against transformation and may provide new markers for tumor staging, for assessment of the relative risk of tumor formation, and open new opportunities for therapeutic intervention.
Journal Article
Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma
TL;DR: It is suggested that HBxAg binds to p53 and that this association is important to the development of PHC.